[theold]

The trials pitted Valneva’s candidate against the AstraZeneca (NASDAQ:AZN) vaccine that is among the six most widely used in the world against Covid. Valneva claims the results showed its candidate has superior neutralizing antibody levels compared to the British firm’s vaccine.

The outcome may suggest that both vaccines used in the study prevented severe Covid-19 caused by the circulating variants including the predominant Delta, Valneva said.


https://sg.finance.yahoo.com/news/valnev...16720.html